Clinical course showing improvement of the bone lesions and bone formation following treatment with lenalidomide/dexamethasone (RD). The changes in serum alkaline phosphatase (ALP) levels indicate normal range. BD (w), bortezomib/dexamethasone weekly; HD-CY, high dose cyclophosphamide; HD-MEL, high dose melphalan; BD (m), bortezomib/dexamethasone monthly; BD (tw), bortezomib/dexamethasone twice weekly; Day 0, autologous peripheral blood stem cell transplantation; PET CT, F18-fluorodeoxyglucose-positron emission tomography/computed tomography; X-P, plain X-ray imagining.